Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts

FDA drug recalls in 2022

Every FDA drug recall initiated in 2022, newest first, with its risk class, status and the reason the FDA recorded. Use the cause and risk filters to narrow the year down.

1,390 recalls, newest first.

Class II · Moderate risk

Quinapril Tablets USP

CGMP Deviations: Detection of N-Nitroso-quinapril impurity above the acceptable daily intake limit.

Terminated Nitrosamine impurity Lupin Pharmaceuticals Inc. NDC 68180-558-09 D-0089-2023
Class II · Moderate risk

Quinapril Tablets USP

CGMP Deviations: Detection of N-Nitroso-quinapril impurity above the acceptable daily intake limit.

Terminated Nitrosamine impurity Lupin Pharmaceuticals Inc. NDC 68180-554-09 D-0088-2023
Class I · High risk

Advil Liqui Gels

Labeling: Illegible Label; the adhesive migrated onto a portion of the label, causing it to tear when peeled back

Terminated Labeling / mix-up Glaxosmithkline Consumer Healthcare Holdings DBA Haleon D-0183-2023
Class I · High risk

Advil Liqui Gels

Labeling: Illegible Label; the adhesive migrated onto a portion of the label, causing it to tear when peeled back

Terminated Labeling / mix-up Glaxosmithkline Consumer Healthcare Holdings DBA Haleon D-0182-2023
Class I · High risk

Advil (ibuprofen)

Labeling: Illegible Label; the adhesive migrated onto a portion of the label, causing it to tear when peeled back

Terminated Labeling / mix-up Glaxosmithkline Consumer Healthcare Holdings DBA Haleon D-0181-2023
Class III · Low risk

Lacosamide Oral Solution

Failed Excipient Specifications: out of specification result observed for p-Hydroxybenzoic Acid content

Terminated Failed specification Camber Pharmaceuticals, Inc NDC 31722-627-26 D-0094-2023
Class II · Moderate risk

TUMS Antacid

Presence of Foreign Substance: The foreign material is primarily comprised of glass mineral wool.

Completed Particulate / foreign matter GlaxoSmithKline Consumer Healthcare Holdings LLC D-0079-2024
Class II · Moderate risk

TUMS Antacid

Presence of Foreign Substance: The foreign material is primarily comprised of glass mineral wool.

Completed Particulate / foreign matter GlaxoSmithKline Consumer Healthcare Holdings LLC D-0078-2024
Class II · Moderate risk

TUMS Antacid

Presence of Foreign Substance: The foreign material is primarily comprised of glass mineral wool.

Completed Particulate / foreign matter GlaxoSmithKline Consumer Healthcare Holdings LLC D-0077-2024
Class II · Moderate risk

TUMS Antacid

Presence of Foreign Substance: The foreign material is primarily comprised of glass mineral wool.

Completed Particulate / foreign matter GlaxoSmithKline Consumer Healthcare Holdings LLC D-0076-2024
Class II · Moderate risk

TUMS Antacid

Presence of Foreign Substance: The foreign material is primarily comprised of glass mineral wool.

Completed Particulate / foreign matter GlaxoSmithKline Consumer Healthcare Holdings LLC D-0075-2024
Class II · Moderate risk

TUMS Antacid

Presence of Foreign Substance: The foreign material is primarily comprised of glass mineral wool.

Completed Particulate / foreign matter GlaxoSmithKline Consumer Healthcare Holdings LLC D-0074-2024
Class II · Moderate risk

TUMS Antacid

Presence of Foreign Substance: The foreign material is primarily comprised of glass mineral wool.

Completed Particulate / foreign matter GlaxoSmithKline Consumer Healthcare Holdings LLC D-0073-2024
Class I · High risk

Iohexol (300 mg Iodine/mL)

Labeling: Label Error on Declared Strength: syringes mislabeled as 300 mg iodine/mL contained product 350 mg iodine/mL

Terminated Labeling / mix-up BayCare Integrated Service Center, LLC /dba BayCare Central Pharmacy D-0086-2023
Class I · High risk

8.4% Sodium Bicarbonate Injection

Defective Container: Complaints received of vial breakage and glass flying when pressurized while preparing the product for administration.

Terminated Packaging defect Exela Pharma Sciences LLC NDC 72572-740-20 D-0080-2023
Class I · High risk

8.4% Sodium Bicarbonate Injection

Defective Container: Complaints received of vial breakage and glass flying when pressurized while preparing the product for administration.

Terminated Packaging defect Exela Pharma Sciences LLC NDC 51754-5001-5 D-0079-2023
Class II · Moderate risk

Sensorcaine-MPF

Subpotent Drug: Testing results below the defined limit for the epinephrine portion of this product.

Terminated Wrong potency / content Fresenius Kabi USA, LLC NDC 63323-468-01 D-0129-2023

Recalls by year